Cholesterol guidelines updated to recommend earlier screening and lifetime risk focus

The American College of Cardiology and the American Heart Association released updated cholesterol guidelines published March 13 that replace the 2018 guidance and emphasize earlier screening — including in some people in their 30s — and a shift toward assessing lifetime cardiovascular risk with a new PREVENT-ASCVD calculator.

The ACC and AHA issued updated cholesterol guidance published March 13 in the Journal of the American College of Cardiology and in Circulation. The update replaces the 2018 guidelines and gathers current advice on cholesterol and blood fats into a single reference for clinicians. It emphasizes earlier screening and a focus on lifetime exposure to unhealthy cholesterol levels rather than only short-term risk. The committee notes that elevated LDL cholesterol is common among U.S. adults and remains an important contributor to cardiovascular disease. Key points: - The new guidance was published March 13 and replaces the 2018 cholesterol guidelines. - Clinicians are advised to consider screening and possible treatment earlier, including in some people in their 30s, especially if LDL remains persistently high. - The guideline promotes assessing long-term risk and recommends a new PREVENT-ASCVD risk calculator that estimates both 10-year and 30-year cardiovascular risk for adults ages 30 to 79. - The ACC and AHA recommend routine consideration of additional blood tests (biomarkers) that may reveal risks not captured by standard cholesterol panels. - Specific cholesterol targets are reinstated, with treatment goals set based on a person’s risk; lifestyle measures remain central, and earlier use of lipid-lowering medication such as statins is supported when lifestyle changes alone do not achieve desired lipid levels. Summary: The guidance shifts emphasis toward earlier detection and a lifetime-risk approach, and it consolidates recommendations into a single clinician reference. It also introduces the PREVENT-ASCVD tool and encourages consideration of additional biomarkers; implementation and clinical uptake are undetermined at this time.